If you suffered losses exceeding $100,000 in Merck between February 3, 2022 and February 3, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at ...

2025年3月15日（GLOBE NEWSWIRE）——Faruqi & Faruqi律师事务所的证券诉讼合伙人詹姆斯（乔希）·威尔逊鼓励在2022年2月3日至2025年2月3日期间购买或获取默克证券的投资者直接联系他，讨论他们的法律选项。该律师事务所目前正在调查对默克（Merck & Co., Inc.，NYSE: MRK）的潜在索赔，并提醒投资者，申请担任联席原告的截止日期是2025年4月14 ...

购买默克证券的投资者可能有权在无需支付自付费用的情况下获得赔偿。欲加入此项集体诉讼，您可访问 https://rosenlegal.com/submit-form/?case_id=34975 ...

Despite this potential, the stock has fallen by 25% in the past 12 months -- so is it a bargain buy right now? During the ...

Within that group, biotechnology giant Amgen (NASDAQ: AMGN) has been the best-performing stock in 2025, returning an ...

Merck's revenues are driven by cancer med Keytruda, which faces patent expiry by 2028. See why I rate MRK stock a hold.

CASE DETAILS: According to the complaint, defendants provided investors with material information concerning Merck’s expected revenue of $11 billion from sales of Gardasil by 2030. Defendants ...

Rising competitive pressure on the diabetes franchise and persistent challenges for its human papillomavirus vaccine, Gardasil in China remain overhangs. There are concerns about Merck’s ability ...

Biopharma giant MSD says it stands ready to pursue new approaches to advance public health in China after its GARDASIL ...